GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Mechanisms of ATR Targeting and Regulation

$250,980
University Of Wisconsin Madison · R01 · FY2003 · GM

CDK inhibitor regulation during the Xenopus cell cycle

$250,900
University Of Texas Hlth Sci Ctr San Ant · R01 · FY2004 · GM

CDK inhibitor regulation during the Xenopus cell cycle

$250,900
University Of Texas Hlth Sci Ctr San Ant · R01 · FY2003 · GM

Project 2: Inter-Relationship of Disparities, the Microbiome, Innate Immune System and Immunotherapy Response in Endometrial Cancer

$250,567
Victoria Lin Bae-Jump · Univ Of North Carolina Chapel Hill · U54 · FY2025 · CA

Treg-depleting immunotherapy

$250,548
Peter David Suzdak · Sonoval Llc · R44 · FY2020 · CA

Structure and Function of SET Domain Methyltransferases

$250,497
Raymond C Trievel · University Of Michigan At Ann Arbor · R01 · FY2007 · GM

NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY

$250,404
University Of Arizona · U19 · FY2002 · CA

NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY

$250,404
University Of Arizona · U19 · FY2001 · CA

RNA editing in islet function and inflammation

$250,355
Alvin Carter Powers · Vanderbilt University Medical Center · R01 · FY2025 · DK

Project 4-Monika Rak

$250,347
Monika Rak · Lsu Health Sciences Center · P20 · FY2024 · GM

Project 4-Monika Rak

$250,347
Monika Rak · Lsu Health Sciences Center · P20 · FY2023 · GM

Project 4-Monika Rak

$250,347
Monika Rak · Lsu Health Sciences Center · P20 · FY2022 · GM

Project 3: Immune Checkpoint Inhibition Therapy Enhanced by Integrated Photodynamic Treatment and Image Guidance in Preclinical Models of Pancreatic Cancer

$250,024
Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2022 · CA

P53 MEDIATED G2/M CHECKPOINT CONTROL

$250,024
Thomas Jefferson University · R01 · FY2002 · CA

Core 1: Mouse Model and Tissue Biobank Core

$250,014
Roger S Lo · Institute For Systems Biology · U54 · FY2023 · CA

Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis

$250,000
Naiyer A Rizvi · Sloan-Kettering Inst Can Research · U01 · FY2008 · CA

Tumor-associated pDC (TApDC) and HIV infection in programing tumor microenvironment

$249,999
Taofeek K Owonikoko · University Of Maryland Baltimore · P30 · FY2024 · CA

Checkpoint Abrogation and MEK 1/2 Inhibition in Myeloma

$249,983
Steven Grant · Virginia Commonwealth University · R01 · FY2009 · CA

Arginine Availability, Modulated by MDSC, Regulates T Cell Function in Cancer

$249,940
Augusto C Ochoa · Lsu Health Sciences Center · R01 · FY2010 · CA

Arginine Availability, Modulated by MDSC, Regulates T Cell Function in Cancer

$249,940
Augusto C Ochoa · Lsu Health Sciences Center · R01 · FY2009 · CA

A novel oncolytic virus for pancreatic cancer immunotherapy

$249,900
Omeed Moaven · Lsu Health Sciences Center · P20 · FY2024 · GM

Functional study of C53 protein as a novel regulator of checkpoint kinases

$249,900
Honglin Li · Lurie Children'S Hospital Of Chicago · R01 · FY2009 · GM

Consolidated Basic Cancer Research Program

$249,893
Dario C. Altieri · Wistar Institute · P30 · FY2023 · CA

Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy

$249,806
Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2020 · CA

Molecular basis of neuronal dysfunction in AIDS

$249,728
Francesca Peruzzi · Temple Univ Of The Commonwealth · R01 · FY2008 · MH